Table 2.

Characteristics of Cases

	No. of cases	Sustained taper absolute dose reduction from peak dose, MME	Sustained taper percent dose reduction from peak dose, %	Sustained taper dose, MME
		Median [IQR]	Median [IQR]	Median [IQR]
Total	894	60 [44–90]	69 [58–91]	24 [7–38]
Type of taper achieved
Discontinuation	200	75 [60–100]	100 [100–100]	0 [0–0]
Low ≤ 30 MME	410	47 [35–62]	69 [58–81]	23 [15–28]
Reduced ≥ 50%	284	75 [53–122]	58 [53–66]	50 [38.5–67.5]
Peak dose prior to taper
31–< 50 MME	21	25 [18–40]	51 [40–100]	21 [0–27]
50–< 90 MME	481	47 [37–59]	70 [57–93]	20 [5–28]
90–< 120 MME	165	72 [60–90]	71 [61–100]	27 [0–39]
120–< 150 MME	84	87 [75–114]	65 [58–92]	44 [10.5–56]
150–< 200 MME	66	122 [103–145]	68 [59–83]	54 [27–67]
200+ MME	77	192 [148–269]	68 [58–77]	90 [57–120]
Year of cohort entry
2011	531	66 [49–100]	68 [57–89]	27 [8–45]
2012	138	51 [39–80]	66 [57–85]	24.5 [11–31]
2013	81	53 [42–77]	73 [60–91]	20 [7–30]
2014	79	58 [43–75]	77 [61–100]	19 [0–28]
2015	65	55 [40–70]	74 [59–100]	19 [0–29]
Age group at cohort entry, years
18–40	87	61 [44–92]	77 [62–88]	20 [7–30]
41–60	507	62 [45–91]	68 [57–93]	26 [6–41]
61+	300	58 [43–89]	68 [57–89]	24 [9–34]
Sex
Female	555	60 [44–90]	68 [58–89]	25 [8–37]
Male	339	61 [45–90]	71 [57–100]	24 [0–40]
Race
White	725	60 [44–90]	69 [58–91]	24 [7–38]
African-American	39	53 [43–90]	77 [56–100]	21 [0–30]
American Indian	19	61 [39–93]	69 [54–87]	23 [18–30]
Alaskan Native
Asian	4	62.5 [45–87.5]	63 [61–82]	26.5 [11.5–41.5]
Hawaiian or other	3	50 [34–74]	56 [52–62]	40 [32–46]
Pacific Islander
Other	16	55 [40–88.5]	61 [53–70]	30 [24.5–43]
Mixed (more than 1)	26	61 [45–68]	67 [55–84]	26 [9–41]
Hispanic origin
No	798	60 [44–90]	69 [57–90]	25 [8–37]
Yes	33	72 [45–89]	67 [59–100]	25 [0–40]